Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Stock Report

| More

SPARC and Sun Pharma enter into a worldwide license agreement for SCD-044, a potential treatment for atopic dermatitis, psoriasis and other auto-immune disorders

Posted On: 2020-05-28 17:29:08

Sun Pharma Advanced Research Company Ltd. (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872, "SPARC") and Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced a worldwide licensing agreement on the development and commercialization of SCD-044 which is being evaluated as a potential oral treatment for atopic dermatitis, psoriasis and other auto-immune disorders. SCD-044 is entering phase 2 clinical trials.

Under terms of the license agreement, Sun Pharma will pay SPARC an upfront payment of US$ 20 million. SPARC will also be eligible to receive up to US$ 125 million as milestone payments contingent upon the achievement of clinical, regulatory and sales milestones, as well as tiered royalties on sales. Sun Pharma will be responsible for the development, regulatory filings, manufacturing and commercialization of the product globally.

"SPARC is committed to progressing its pipeline to address the needs of patients. We are proud to be partnering with a global organization with a footprint in auto-immune disorders" said Anil Raghavan, CEO, SPARC. This agreement with Sun Pharma follows the recent announcement that SPARC has acquired Bioprojet SCR's share of rights to SCD-044.

"The in-licensing of SCD-044 adds to our specialty pipeline of innovative dermatology products. It also demonstrates our commitment to this important segment with significant unmet medical needs. SCD-044 may offer an alternate treatment option for patients in this segment who require systemic treatment and may offer benefits in terms of efficacy and safety over existing oral treatments for this population. SCD-044 has the potential to improve the current oral standard of care." said Dilip Shanghvi, Managing Director, Sun Pharma.

SCD-044 is a novel orally bio-available Sphingosine-1-P (S1P1) receptor agonist for the treatment of inflammatory diseases such as atopic dermatitis and psoriasis. S1P1 receptor agonists are promising for the treatment of autoimmune inflammatory diseases as they cause diminished migration of lymphocytes out of lymphatic tissue. This results in a decrease of circulating lymphocytes, thereby reducing inflammation.

The phase 1 study of SCD-044 has been completed in healthy volunteers. This study established clinical proof-of-concept for SCD-044 in terms of its pharmacodynamics effects. Lymphocyte count reduction, a surrogate marker of efficacy for S1P1R agonists was observed at all dose levels evaluated.

Shares of SUN PHARMA ADVANCED RESEARCH COMPANY LTD. was last trading in BSE at Rs.135.15 as compared to the previous close of Rs. 126.65. The total number of shares traded during the day was 131160 in over 2789 trades.

The stock hit an intraday high of Rs. 139.3 and intraday low of 127.15. The net turnover during the day was Rs. 17495964.

Shares of SUN PHARMACEUTICAL INDUSTRIES LTD. was last trading in BSE at Rs.459.25 as compared to the previous close of Rs. 450.55. The total number of shares traded during the day was 332089 in over 7515 trades.

The stock hit an intraday high of Rs. 461.8 and intraday low of 444.75. The net turnover during the day was Rs. 151327616.

Source: Equity Bulls

Click here to send ur comments or to

Other Headlines:

Cipla Limited updates on US arm's agreement with Pulmatrix, Inc. USA

The Phoenix Mills Limited board approves fund raising proposal

City Union Bank Ltd to raise Rs. 600 crore through QIP

First Container vessel carrying Export Cargo from India to Bangladesh

MBL's Performance for the year ended 31st March 2020

Den Networks Ltd board to announce first quarter results on July 20, 2020

AU Small Finance Bank Ltd board to approve 1st quarter results on July 23, 2020

Sundaram-Clayton Ltd board to consider Q1FY21 results on July 30, 2020

Kwality Pharmaceuticals Ltd FY2020 consolidated PAT up at Rs. 8.31 crore

Mahindra Holidays & Resorts India Ltd board to approve 1st quarter results on July 31, 2020

Mahindra Lifespaces appoints Parveen Mahtani as Chief Legal Officer

Vedanta launches phase 2 of 'Meal for All' program

Muthoot Finance launches cashback scheme for customers amid COVID-19

Kanchi Karpooram Ltd's expansion delayed, expects to complete by December 2020

International Conveyors Ltd board recommends dividend of Rs. 0.20 for FY20

CRISIL Ltd board to Q2CY2020 results on July 21, 2020

Godrej Industries Ltd board approves raising Rs. 750 crore through NCDs

Aditya Birla Capital's subsidiaries record over four million customer interactions on digital service platforms

Shiva Texyarn launches Medic Virostat Mask at Rs 49

YES BANK FPO of Rs. 15,000 crore opens on July 15, sets Price Band between Rs. 12 to Rs. 13

COVID-19: Liberty Shoes expects 35%-45% fall in revenues this fiscal

Acuite downgrades long term rating of Goa Carbon Ltd

Hatsun Agro Product Ltd board to approve Q1 FY2021 results and interim dividend on July 21, 2020

TVS Motor Company Ltd board to consider 1st quarter results on July 29, 2020

Rajratan Global Wire Ltd board to announce Q1FY21 results on July 21, 2020

5paisa Capital Ltd swings to profit in Q1 FY2020-21

Universal Autofoundry Ltd FY2020 consolidated loss at Rs. 4.05 crore

India Home Loan Ltd Board recommends Final Dividend of Rs. 0.15

HDFC board to announce Q1FY21 results on July 30, 2020

India Home Loan Ltd Q4 FY20 PAT soars to Rs. 1.64 crore

The South India Paper Mills Ltd board to announce Q1FY21 results on July 30, 2020

Asian Oilfield Services Ltd - Business Update

L&T board to announce Q1 FY2021 results on July 22, 2020

HeidelbergCement India Ltd board to announce quarterly results on July 22, 2020

Asahi Songwon Colors Ltd board to approve Q1FY21 results on July 21, 2020

Mr. Subramanian Sarma Inducted as Executive Director on L&T Board, Mr. S V Desai & Mr. T Madhava Das elevated

Glenmark commences 1000 patients Post Marketing Surveillance study with COVID-19 who are administered FabiFlu®

Quick Heal redefines Consumer Security in India

CARE reaffirms rating of Bhageria Industries Limited

Adani Ports and Special Economic Zone Limited updates on ratings from global rating agencies

Birlasoft intelliOpen™ supports safe return-to-work strategies

Morgan Stanley to Consolidate Mumbai GIC operations to a Single Campus at Oberoi Realty's Commerz III Building in Goregaon

Steel Strips Wheels Ltd receives new orders from EU and USA

MBL Infrastructures Ltd gets three favorable arbitration awards

Gitanjali Gems Ltd to be liquidated

Qualcomm Ventures to invest Rs. 730 crore in Jio Platforms

Aarti Surfactants Limited to list on July 14, 2020

Hindustan Unilever Ltd board to consider quarterly results on July 21, 2020

Avenue Supermarts Ltd reports earnings for Q1FY21

Clariant Chemicals' declares Special Interim Dividend of Rs. 140/- per share

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019